Abstract: The medicament for the prevention or the relief of poisoning by large clostridial cytotoxins (LCTs), in particular Clostridium difficile toxins A and B (TcdA and TcdB), is characterized by containing as active ingredient at least one effector, namely an inhibitor or activator of the autocatalytic protease activity of LCTs (large clostridial cytotoxins).

Abstract: The present invention relates to a compound of formula (I) wherein R1, R2 and R3 are as defined in the description and the physiologically acceptable salts thereof as well as the physiologically acceptable solvates of the compounds of formula I and of the salts thereof. The compounds of formula I are suitable for treating tumors.

Abstract: The present invention relates to a balloon catheter system for draining and/or supplying fluid from/into hollow organs, body cavities or cysts, comprising a conduit catheter with an open distal end, a hollow needle guided in a separate guide conduit and a balloon surrounding the catheter stem at the distal end of the conduit catheter. The conduit catheter with the hollow needle can be inserted from outside into the hollow organ via a guide catheter, into the body cavity or cyst, the balloon can be filled with filling medium via the hollow needle through an opening formed in the guided duct and provided in the lumen of the balloon, and it can be fixed in the hollow organ, body cavity or cyst. The hollow needle can be removed from the guide duct after filling the balloon. The balloon and the conduit catheter remain in the hollow organ, body cavity or cyst.

Abstract: The invention relates to inorganic, intermetallic, inhomogeneous compounds having a magnetic resistance effect and an intrinsic field sensitivity of at least 7% at 1 T at room temperature. The invention further relates to a method for the production and use thereof, particularly as magnetic field sensors or in spin electronics.

Abstract: The invention relates to initial 68Ge/Ga-generator elute which is guided directly to a cation exchanger, whereon 68Ga is quantitatively absorbed and is cleaned simultaneously in a chemical and radio chemical manner. Subsequently, the 68Ga-radio nuclide is combined with a radio pharmaceutical substance by a marking precursor made of a ligand or a peptide or a protein which is cross-linked in a covalent manner to a ligand.

Abstract: The invention relates to the rational mutagenesis of polypeptides of ?/? T-cell receptors that mediate an oncogen-specific T-cell response, nucleic acids encoding these and their use in the therapy, diagnosis and/or prevention of cancerous diseases. The invention further relates to a T-cell response-mediating MDM2-protein-specific ?/? T-cell receptor, which has been rationally mutated by means of the method according to the present invention, and the uses thereof.

Abstract: The present invention relates to an electrophoresis apparatus comprising a gel chamber for receiving electrophoresis medium, a removable gel system, which is arranged in the gel chamber, having a separation gel for the electrophoretic separation of biological molecules such as nucleic acids or proteins, electric contact elements for generating an electric field through the separation gel, optionally a lid for fastening on the gel chamber, characterized in that the separation gel is delimited at least at one side by a spacer element which is in the form of a collector and comprises a plurality of sample collection containers, which are arranged one next to the other, for fractionating and for collecting the electrophoretically separated molecules. The invention further relates to a method for the electrophoretic separation and collection of biological molecules by way of a two-dimensional gel electrophoresis.

Abstract: The present invention relates to novel heparin-nitroxide derivatives comprising heparin and at least two and more nitroxides/polynitroxide radicals that are covalently coupled to heparin by derivatisation of glycosaminoglycan carboxyl or amino groups. The heparin-nitroxide derivatives are useful as therapeutic or diagnostic agents. This invention further concerns novel methods for the production of the heparin-nitroxide agents, and methods of their uses for specifically targeting and labelling of biological vessels. The inventions also suggest the uses of the heparin-nitroxide derivatives for treatment of oxidative stress-mediated diseases. Furthermore, the heparin-nitroxide derivatives according to the present invention are in particular useful for electron paramagnetic resonance imaging (EPRI), for magnetic resonance imaging (MRI), and for preservation of biological transplants.

Abstract: The medicament for the prevention or the relief of poisoning by large clostridial cytotoxins (LCTs), in particular Clostridium difficile toxins A and B (TcdA and TcdB), is characterized by containing as active ingredient at least one effector, namely an inhibitor or activator of the autocatalytic protease activity of LCTs (large clostridial cytotoxins).

Abstract: A new class of non-glycosidic and non-peptidic inhibitors of selectins with low molecular weight according to the general formula 1 is described, as well as methods for their production. These compounds represent a new class of non-toxic, in vivo anti-inflammatory effective inhibitors of selectins, and do not exhibit the disadvantages of the glycosidic inhibitor complexes, and are furthermore more potent in vitro, compared to the known drug bimosiamose. Furthermore, medicaments containing the compounds and their uses in the treatment of diseases are described.

Abstract: The present invention relates to a pharmaceutical preparation, comprising at least one Toll-like receptor ligand and at least one peptide. The invention also relates to the use of such a pharmaceutical preparation and to a vaccination method.